Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 5
2004 7
2005 9
2006 12
2007 41
2008 37
2009 29
2010 29
2011 16
2012 14
2013 13
2014 10
2015 14
2016 19
2017 11
2018 12
2019 12
2020 10
2021 11
2022 9
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Stewart AK, et al. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482145 Free article. Clinical Trial.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Cornely OA, et al. Among authors: petrini m. N Engl J Med. 2007 Jan 25;356(4):348-59. doi: 10.1056/NEJMoa061094. N Engl J Med. 2007. PMID: 17251531 Free article. Clinical Trial.
Piezoelectric Signals in Vascularized Bone Regeneration.
D'Alessandro D, Ricci C, Milazzo M, Strangis G, Forli F, Buda G, Petrini M, Berrettini S, Uddin MJ, Danti S, Parchi P. D'Alessandro D, et al. Among authors: petrini m. Biomolecules. 2021 Nov 20;11(11):1731. doi: 10.3390/biom11111731. Biomolecules. 2021. PMID: 34827729 Free PMC article. Review.
Editorial: In Search of In vivo MSC.
Pacini S, Petrini M. Pacini S, et al. Among authors: petrini m. Front Cell Dev Biol. 2017 May 29;5:60. doi: 10.3389/fcell.2017.00060. eCollection 2017. Front Cell Dev Biol. 2017. PMID: 28611984 Free PMC article. No abstract available.
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.
Bachy E, Savage KJ, Huang H, Kwong YL, Gritti G, Zhang Q, Liberati AM, Cao J, Yang H, Hao S, Hu J, Zhou K, Petrini M, Russo F, Zhang H, Sang W, Ji J, Ferreri AJM, Damaj GL, Liu H, Zhang W, Ke X, Ghiggi C, Huang S, Li X, Yao H, Paik J, Novotny W, Zhou W, Zhu H, Zinzani PL. Bachy E, et al. Among authors: petrini m. Blood Adv. 2023 Aug 22;7(16):4435-4447. doi: 10.1182/bloodadvances.2022009575. Blood Adv. 2023. PMID: 37276067 Free PMC article. Clinical Trial.
Lithium in the treatment of neutropenia.
Petrini M, Azzarà A. Petrini M, et al. Curr Opin Hematol. 2012 Jan;19(1):52-7. doi: 10.1097/MOH.0b013e32834da93b. Curr Opin Hematol. 2012. PMID: 22123660 Retracted. Review.
Gliptins.
Focosi D, Kast RE, Petrini M. Focosi D, et al. Among authors: petrini m. Lancet. 2007 Jan 27;369(9558):269-70. doi: 10.1016/S0140-6736(07)60137-8. Lancet. 2007. PMID: 17258656 No abstract available.
266 results